Literature DB >> 10504456

Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides.

V Blaschke1, K Reich, P Middel, M Letschert, F Sachse, S Harwix, C Neumann.   

Abstract

Interleukin-16 is a soluble ligand to the CD4 molecule with chemotactic properties for CD4+ cells and a competence growth factor for CD4+ T cells, upregulating HLA-DR and the interleukin-2 receptor CD25. There is also evidence for a synergistic effect of interleukin-16 and interleukin-2 on the activation of CD4+ T cells. The infiltrate in mycosis fungoides, the most common cutaneous T cell lymphoma, is typically CD4+. We tested the possibility that interleukin-16 is involved in the formation and progression of these lesions. By reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated. By competitive reverse transcription-polymerase chain reaction, interleukin-16 mRNA expression increased with disease stage. Secreted interleukin-16 was detected by enzyme-linked immunosorbent assay in both Th1- and Th2-like T cell clones (as characterized by their production of interferon-gamma and interleukin-4) grown from lesional dermis and epidermis. By immunohistochemistry and in situ hybridization, infiltrating lymphocytes were the main producers of interleukin-16 whereas keratinocytes and endothelial cells remained negative. Atypical cells with convoluted nuclei were also positive. In advanced mycosis fungoides stages, many blast-like cells were positive, but some larger blasts remained negative. Interleukin-16 expression correlated positively with the expression of interleukin-2 and its receptor CD25 in individual skin lesions. Interleukin-2 expression, however, was weak or absent in samples from uninvolved skin, healthy controls and lesional psoriasis. Given the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504456     DOI: 10.1046/j.1523-1747.1999.00717.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Significant Association of Interleukin-16 Genetic Variations to Taiwanese Lung Cancer.

Authors:  Meng-Feng Wu; Yun-Chi Wang; Te-Chun Shen; Wen-Shin Chang; Hsin-Ting Li; Cheng-Hsi Liao; Chi-Li Gong; Zhi-Hong Wang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Interaction of Interleukin-16 Genotypes With Betel Quid Chewing Behavior on Oral Cancer in Taiwan.

Authors:  Liang-Chun Shih; Wen-Shin Chang; Hsu-Tung Lee; Yun-Chi Wang; Zhi-Hong Wang; Che-Yi Chao; Chien-Chih Yu; Hui-Yi Lin; Te-Chun Shen; Chien-Chung Kuo; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease.

Authors:  P Middel; K Reich; F Polzien; V Blaschke; B Hemmerlein; J Herms; M Korabiowska; H J Radzun
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

4.  Human mid-gestation amniotic fluid contains interleukin-16 bioactivity.

Authors:  Catherine A Thornton; Judith A Holloway; Janis K Shute; John W Holloway; Norma D Diaper; John O Warner
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

5.  The association of interleukin-16 gene polymorphisms with IL-16 serum levels and risk of nasopharyngeal carcinoma in a Chinese population.

Authors:  Xue Qin; Qiliu Peng; Xiaoxia Lao; Zhiping Chen; Yu Lu; Xianjun Lao; Cuiju Mo; Jingzhe Sui; Junrong Wu; Limin Zhai; Shi Yang; Shan Li; Jinmin Zhao
Journal:  Tumour Biol       Date:  2013-10-08

6.  Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease.

Authors:  Dorota Purzycka-Bohdan; Aneta Szczerkowska-Dobosz; Monika Zablotna; Justyna Wierzbicka; Anna Piotrowska; Michal A Zmijewski; Boguslaw Nedoszytko; Roman Nowicki
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

Review 7.  Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover.

Authors:  Thorbjørn Krejsgaard; Lise M Lindahl; Nigel P Mongan; Mariusz A Wasik; Ivan V Litvinov; Lars Iversen; Erik Langhoff; Anders Woetmann; Niels Odum
Journal:  Semin Immunopathol       Date:  2016-10-07       Impact factor: 9.623

8.  Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis.

Authors:  Victor Hugo de Souza; Josiane Bazzo de Alencar; Bruna Tiaki Tiyo; Hugo Vicentin Alves; Evelyn Castillo Lima Vendramini; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Oncotarget       Date:  2020-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.